Lockheed Martin Investment Management Co. Makes New $2.62 Million Investment in Amgen Inc. $AMGN

Lockheed Martin Investment Management Co. bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,300 shares of the medical research company’s stock, valued at approximately $2,624,000.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC raised its position in shares of Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after buying an additional 114 shares in the last quarter. Accurate Wealth Management LLC boosted its position in shares of Amgen by 23.0% during the 2nd quarter. Accurate Wealth Management LLC now owns 3,611 shares of the medical research company’s stock valued at $1,085,000 after acquiring an additional 676 shares during the last quarter. BCS Wealth Management grew its stake in Amgen by 19.2% in the 2nd quarter. BCS Wealth Management now owns 942 shares of the medical research company’s stock worth $263,000 after buying an additional 152 shares in the last quarter. Finally, Regatta Capital Group LLC increased its stake in Amgen by 3.8% in the second quarter. Regatta Capital Group LLC now owns 6,531 shares of the medical research company’s stock valued at $1,824,000 after acquiring an additional 241 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of Amgen stock opened at $347.07 on Friday. The firm has a market cap of $186.89 billion, a PE ratio of 26.82, a price-to-earnings-growth ratio of 3.06 and a beta of 0.45. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $349.98. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The company’s fifty day simple moving average is $331.91 and its two-hundred day simple moving average is $307.18.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the business posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is 73.57%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. Company insiders own 0.76% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board raised the dividend to $2.52, a direct return-of-capital boost that supports income-oriented investors and helps explain buying interest. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Stock momentum: AMGN hit a 52?week high (~$346.41), signalling strong market demand and momentum buying following the dividend and pipeline news. Amgen stock hits 52-week high at $346.41
• Positive Sentiment: Pipeline expansion: Amgen broadened its obesity strategy via a collaboration with Ro on GLP?1 therapies, which markets view as a growth opportunity in a hot therapeutic class. Amgen expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: Analyst/industry bullish thesis: A Seeking Alpha piece highlights MariTide’s obesity and T2D potential as a multi?year growth driver, supporting a constructive long?term view (speculative but market?relevant). Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Neutral Sentiment: Near?term focus on earnings and fundamentals: Coverage notes investor attention on upcoming earnings and core fundamentals — supportive but not an immediate catalyst. Amgen Stock Outlook: Score And Near-Term Earnings Focus
• Neutral Sentiment: Dividend-yield screen visibility: Amgen appears in dividend?focused lists (e.g., “Dogs of the Dow” coverage), which can attract income investors but is not a direct operational catalyst. The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8%
• Negative Sentiment: Analyst downgrade: Sanford C. Bernstein cut AMGN to a Hold/lowered its rating, a headwind that can cap upside as some funds and quant models react to the call. Bernstein downgrades Amgen (AMGN) to a Hold Amgen (NASDAQ:AMGN) Stock Rating Lowered by Sanford C. Bernstein
• Negative Sentiment: Legal risk: Sagebrush has sued Amgen over a dispute tied to the 340B drug?pricing program; litigation and potential policy scrutiny introduce near?term uncertainty and could affect stakeholder relations. Sagebrush sues Amgen over 340B program row Amgen (AMGN) Faces 340B Lawsuit

Wall Street Analyst Weigh In

Several brokerages have issued reports on AMGN. Deutsche Bank Aktiengesellschaft upped their target price on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research note on Tuesday, November 11th. Bank of America upped their price objective on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Cantor Fitzgerald increased their target price on shares of Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Scotiabank started coverage on shares of Amgen in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price target for the company. Finally, Piper Sandler raised their price objective on Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $339.24.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.